(MENAFN- PR Newswire) Separately, the company is also studying placing the novel, small-diameter OmniaSecure defibrillation lead in the left bundle branch (LBB) area, which has the potential to enable ...

Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: ...

Researchers presented late-breaking results at Heart Rhythm 2025 for the LEADR LBBAP (Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing) study that showed the ...

Global LEADR clinical trial meets safety and effectiveness objectives; results presented at Heart Rhythm 2024 and simultaneously published in Heart Rhythm DUBLIN and BOSTON, May 17, 2024 /CNW/ -- ...

Medtronic plc, a global leader in healthcare technology, received US Food and Drug Administration (FDA) approval for the OmniaSecure defibrillation lead for placement within the right ventricle. The ...